Dimerix buys a kidney injury drug; Arpeggio appears to be winding down

July 17, 2026 10:41 AM EDT News Briefing Dimer­ix buys a kid­ney in­jury drug; Arpeg­gio ap­pears to be wind­ing down ENDPOINTS Plus, news about Take­da, No­var­tis and Re­genxbio. 🤝 Mis­sion sells kid­ney in­jury drug to Dimer­ix: Dimer­ix will pay $5 mil­lion up­front … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER